Home > > > Report Detail

Global Pharma US & EU Outlook 2015 : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

Publisher Name :
Date: 26-Jan-2015
No. of pages: 63
Inquire Before Buying

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years several new therapies have been approved in the area of diabetes (SGLT-2, GLP-1 agonists), Multiple Sclerosis, HCV, melanoma and breast cancer from major pharmaceutical companies. Many of them are expected to reach multibillion dollars peak sales in the near-term which is likely to compensate the patent expiry loss in top-line revenue. Novel mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors have also got exclusive attention by large cap Pharma companies. Most companies are in race to acquire assets in these hot therapy areas. Companies who already have these assets are investing heavily in clinical development programs. The interest in pursuing opportunities in Oncology therapy is unhindered for all major Pharma companies. Research investments in oncology likely to continue for several more years due to the significant unmet need exist in this area. But for a few companies, patent expiry impact continues to haunt the top-line and they are finding it difficult to replace declining sales with Proprietary pipeline products. Beyond 2013, the impact of patent loss will further aggravate the revenue decline. They have chosen strategies of prioritization pipeline assets, cost efficiency measures, divestment of non-core assets which yield poor margins and increase focus on therapy areas where they have already proven its mettle. Increase in dividend payout and share repurchase are some near term measures where they are actively participating. Gain in financial strength through divestment of non-core assets (OTC, Animal Health, Consumer health, Diagnostics) will be utilized in pursuing opportunities in high margin therapy areas. At the same time it has becoming more difficult to find such lucrative assets because they are scarce and if available are trading at very high premium in speculation of getting acquired (ex. Roche-Alexion). Going forward, Economies of Scale will also play a major role in swapping the non-core business among major pharma including Vaccines, OTC and animal health to improve margins. Global Pharma continues to remain attractive due to management efforts on the restructuring of entire business model, cost efficiency measures, de-consolidation, acquisition of high value targeted assets, share repurchase program and dividend policy.

Companies Mentioned

AstraZeneca, Merck, Merck KGaA, Novartis, Novo Nordisk, GlaxoSmithKline

Global Pharma US & EU Outlook 2015 : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

Table of Contents

AstraZeneca: Late Stage Pipeline maturing; Focused development on Respiratory, Psoriasis and anti-PD1 will support long term growth
Late stage development is positive but near term pressure immense
R&D Strategy
Long-term CV study and R&D Updates
Brilinta preferred over Plavix in NSTE-ACS patients in the US
Strengthening Business in Diabetes: Acquisition from BMY
Late Stage Development Program
Selumetinib (PhIII, NSCLC, MEK inhibitor, Array Pharma)
Lesinurad (PhIII, URAT1 inhibitor/Hyperuricemia in Gout): did not reduce gout flares but biomarker uric acid level met the end point for approval
Immunotherapy such as anti CTLA and anti-PD1 will strengthen the franchise long-term
Olaparib (PARP Inh, Ovarian cancer)FDA approval
AZD9291 (once daily, oral Tyrosine kinase inhibitor, second-line NSCLC)
Inflammation pipeline: Benralizumab (IL-5R antibody, severe asthma and COPD)
Competitive landscape of cytokine targeted therapies (Tralokinumab, Dupilumab, Lebrikizumab, Mepolizumab
Brodalumab (IL-17RA antibody, Psoriasis, Psoriatic arthritis, Ph III)
Outlook of respiratory franchise going forward: Symbicort, Pearl and Almirall
Anti-infective franchise update (AZD0914)
Nexium OTC approved and generic entry in 2015
The impact of competition on Faslodex
Key milestones
Table 1: Competitive Landscape of Biologics in Severe Asthma
GlaxoSmithKline: Reliance On Low Margin Consumer Health And Vaccines; Unable TRevive
Respiratory Franchise
Respiratory business competitive and large outcome trials became futile
Cost savings tkeep up the operating margins and Potential ViiV IPtfund NVS JV buy-out
Our views on the recently approved drugs from GSK
Eperzan/Tanezeum (Albiglutide): Superior efficacy, better tolerability, ease of administration and compliance benefit should position Albiglutide better than competition in earlier lines of treatment
Mepolizumab (IL-5 inhibitor, UR, once monthly, severe eosinophilic asthma)
Competitive Landscape in severe asthma
Advair Generics
Key milestones
Tables:
Table 1: Bydureon, albiglutide & Victoza Clinical data comparison
Merck: Anti-PD1 and HCV will remain growth drivers going forward!!
IMPROVE-IT Outcome data positive, boosted confidence on other aggressive LDL reducing antibodies therapy
TECOS should help DPP-IV expand their share in a fast growing but highly genericized diabetes market
Acquisition of Cubist for $9.1b will fortify MRK's anti-infective acute hospital care franchise
Collaboration with Bayer for novel cardiovascular assets ($1b+)
Ebola Vaccine acquisition and development
Keytruda Potential
HCV Therapy (grazoprevir/elbasvir, PhIII): targeted for patients whdnot tolerate market leading Sovaldi
Regulatory Developments Gardasil, Belsomra, Grass and Ragweed sublingual allergy tablets, Sugammadex, Odanacatib
Isentress and anti-retroviral development
Diabetes Franchise Ertugliflozin, Januvia/Janumet, Omarigliptin
Keytruda in Second-line NSCLC: Potential additional indications -breast cancer
Remicade Biosimilar impact in Europe: patent expiry in major EU countries in Feb 2015
Key milestones
Tables:
Table 1: Keytruda: List of on-going combination studies
Table 2: On-going Phase III clinical trials for HCV combo
Table 3: On-going clinical trials of Keytruda
Table 4: Competitive Landscape of Anti-PD1

Merck KGaA: Emerging market and anti-PD1 tlift the outlook; Acquisition of Sigma-Aldrich tstabilize business growth
Acquisition of Sigma-Aldrich for $17b would add over $2.1b in topline
Strategic alliances with PFE tdevelop Immuno-oncology pipelineanti-PD1
Erbitux in first line CRC
Erbitux Biosimilar threat is limited due tdifferent manufacturing process in EU/US
Gonal-FBiosimilar competition
Performance materials
Merck Millipore in life sciences tool market (?2.6b)
Consumer Health (?472m ~4% of total sales)
Emerging market continues tsupport the company growth going forward (?1.8b)
Key Milestones
Tables & Charts
Table 1: Merck SeronPhII and PhIII pipeline assets
Chart 1: Merck KGaA Revenue Contribution By Strategic Divisions In 2013
Chart 2: Geographic contribution based on 2013 sales

Novartis: Strengthening Position In Oncology: Heart Failure And Psoriasis Therapy Will Find New Blockbusters
LCZ696 (valsartan with neprilysin inhibitor; twice daily; 8442 patients study) in chronic heart failure patients: Superiority can command higher prices and reimbursement
Rationale for fixed dose combination and Paradigm HF
Patent expiry pressure immense
Targeted and cellular therapy approach in Oncology
CART Technology
Gilenya in Multiple Sclerosis continues tbe key growth driver but market ramp up of Tecfidera (BiogenIdec) is extraordinary despite PML issue
Lemtrada was effective but disease progressed after discontinuation
SERELAXIN (RLX-030) in Acute Heart Failure Unmet need but FDA rejected the approval for more efficacy data
Signifor LAR Approved in Cushing's disease and in acromegaly: Sandostatin LAR Replacement ready in active acromegaly
Signifor/ Pasireotide will penetrate in patients inadequately controlled on Sandostatin. Signifor LAR will take up market share from Sandostatin LAR before the patent expiry in 2017
Secukinumab (Cosentyx) in Plaque Psoriasis Trying TBe Different in a Crowded Space
Current treatments of psoriasis and psoriatic arthritis
Long term safety data is the key for gaining acceptance by Dermatologist
Panobinostat (UR, multiple myeloma, oral HDAC inhibitor) negative recommendation from FDA and safety concerns coupled with nimprovement in overall survival
Patent expiry impact and potential drivers
Sandoz growth tbe driven by biosimilars and respiratory generics
Key milestones
Tables:
Table 1: Efficacy data of LCZ696 in PARADIGM-HF
Table 2: Competition in Acromegaly
Table 3: PASSPORT-Efficacy and Safety Comparison: SIGNIFOR LAR VS. SANDOSTATIN LAR
Table 4: Select Late& Mid-stage pipeline: Plaque Psoriasis
Table 5: PHIII Clinical Data on Plaque Psoriasis of marketed products
Table 6: Patent Expiry Impact Through 2019
Table 7: Sandoz Biosimilar Pipeline Status

NovNordisk: Business growth is limited by pricing and competitive pressures in Diabetes
Xultophy made the entry in Europe-US filing delayed
Competitive pressures on Victoza: Semaglutide needs tshow at least comparable efficacy tTrulicity
Dulaglutide Phase III data non-inferior tVictoza suggests slightly better efficacy with once weekly advantage
Dulaglutide Efficacy and safety data comparison based on ADA conference vs. Victoza (AWARD-6)
Insulin Franchise: Bio-similar insulin's and Novel Insulin's impact cannot be neglected
Liraglutide 3mg obesity (Saxenda): FDA advisory committee voted in favor (14-1)
Clinical safety and Efficacy from SCALE study vs. Contrave
Pricing and Safety likely thamper the market reimbursement and uptake, but delayed progression tpre-diabetes may help
Regulatory concerns of pancreatitis, thyroid cancer & CV risk for high dose regimen in obesity
Haemostasis franchise Turoctocog (NovoEight), NovoThirteen (Cartridecacog), N8-GP
Haemophilia A market size and competition Novoeight competing long-acting pipeline product from Biogen Idec / Sobi, but may score with a first mover advantage in Hemophilia A
Key milestones
Tables:
Table 1: Clinical data comparison of weekly GLP-1 Vs Victoza
Table 2: Obesity Efficacy data comparison vs. marketed drugs

List of Tables

AstraZeneca : Table 1: Competitive Landscape of Biologics in Severe Asthma
GlaxoSmithKline : Table 1: Bydureon, albiglutide & Victoza Clinical data comparison
Merck : Table 1: Keytruda: List of on-going combination studies
Table 2: On-going Phase III clinical trials for HCV combo
Table 3: On-going clinical trials of Keytruda
Table 4: Competitive Landscape of Anti-PD1
Merck KGaA : Table 1: Merck SeronPhII and PhIII pipeline assets
Novartis : Table 1: Efficacy data of LCZ696 in PARADIGM-HF
Table 2: Competition in Acromegaly
Table 3: PASSPORT-Efficacy and Safety Comparison: SIGNIFOR LAR VS. SANDOSTATIN LAR
Table 4: Select Late& Mid-stage pipeline: Plaque Psoriasis
Table 5: PHIII Clinical Data on Plaque Psoriasis of marketed products
Table 6: Patent Expiry Impact Through 2019
Table 7: Sandoz Biosimilar Pipeline Status
NovNordisk : Table 1: Clinical data comparison of weekly GLP-1 Vs Victoza
Table 2: Obesity Efficacy data comparison vs. marketed drugs

List of Charts

Merck KGaA : Chart 1: Merck KGaA Revenue Contribution By Strategic Divisions In 2013
Chart 2: Geographic contribution based on 2013 sales

  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs